Improved control of cisplatin-induced emesis with a metoclopramide-dexamethasone combination

Cancer Chemother Pharmacol. 1984;13(3):235-7. doi: 10.1007/BF00269037.

Abstract

Twenty-four patients receiving combination chemotherapy including cisplatin at a dosage of 50 mg/m2 were entered on this antiemetic randomized open cross-over study. High-dose dexamethasone (DXM) (regimen A) was compared with the combination of DXM and high doses of metoclopramide (MCP) (regimen B). Five patients (20%) treated with regimen A and 13 (54%) treated with regimen B suffered neither nausea nor vomiting (P less than 0.05). Regimen B was found to be significantly more effective than regimen A for all the parameters of evaluation considered. No severe side-effects were observed.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antiemetics*
  • Antineoplastic Combined Chemotherapy Protocols
  • Cisplatin / adverse effects*
  • Dexamethasone / therapeutic use*
  • Female
  • Humans
  • Male
  • Metoclopramide / therapeutic use*
  • Middle Aged

Substances

  • Antiemetics
  • Dexamethasone
  • Metoclopramide
  • Cisplatin